AES Highlights: Resnick on Study 307

Video

Trevor Resnick, MD: This is a [follow-up] from what we had previously discussed with perampanel’s effectiveness for generalized seizures. In this [E2007-G000-307] study, what they had found was that the seizure freedom rate in those patients who were on perampanel for adjunctive therapy was very robust. But 1 of the criticisms would be, well, it’s only a 12-week maintenance phase. How do we know that it continues to work afterward? And what was done in this post hoc analysis of these patients in the open-label extension part of the study was to say, well, of those patients who were seizure-free during this 12-week maintenance period, when they entered the open-label extension, how many of them stayed seizure-free?

And what was gratifying was the fact that I think around 90% of them—even 6 months after entry into the open-label extension—maintained their seizure freedom. And then the numbers dropped a little bit afterward. But often, the reason the numbers dropped as you went to 1 year, 2 years, and 3 years out was because many of the studies were closed out so they couldn’t continue with the open-label extension. But even if you get to 6 months or a year having a 75% or 90% sustained seizure freedom indicates that that data from the controlled study was sustained afterward in the open-label extension.

Yeah. I think it’s very difficult to do a longer, longer study. And so they want to do a study that they believe is clinically meaningful over, say, a 3-month period. And if it is, the data [are] published, and then if you want to look at questions such as sustainability of seizure freedom, that’s when you do an open-label extension.


Related Videos
Claude Steriade, MD, CM
Fred Lado, MD, PhD
Patricia C. Dugan, MD
Iryna Leunikava, MSc
Derek Ems, MPH, CPHQ
Jude Luker, BA (Hons), head of Patient Engagement, Epilepsy and Rare Syndromes (Europe) at UCB Pharma
Claude Steriade, MD, CM
Jude Luker, BA (Hons), head of Patient Engagement, Epilepsy and Rare Syndromes (Europe) at UCB Pharma
© 2024 MJH Life Sciences

All rights reserved.